参考文献
[1] Gao S, Liu Z, Li H, et al. Cardiovascular actions and therapeutic potential of Tanshinone ⅡA[J]. Atherosclerosis, 2012, 220(1):3‑10. DOI: 10.1016/j.atherosclerosis.2011. 06.041.
[2] 钱名堃,扬保津,周明忠. 丹参酮Ⅱ‑A磺酸钠的生产工艺[J]. 中草药通讯,1979,10(6):20‑21,49.
[3] 丹参酮ⅡA磺酸钠注射液规范治疗专家组. 丹参酮ⅡA磺酸钠注射液临床应用专家建议[J].中华老年心脑血管病杂志, 2015, 17(12):1261‑1264. DOI: 10.3969/j.issn. 1009‑0126.2015.12.009.
[4] Mao S, Wang L, Zhao X, et al. Efficacy of sodium Tanshinone ⅡA sulfonate in patients with non‑ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results from a multicentre, controlled, randomized trial[J]. Cardiovasc Drugs Ther, 2021, 35(2):321‑329. DOI: 10.1007/s10557‑020‑07077‑8.
[5] Mao S, Taylor S, Chen Q, et al. Sodium Tanshinone ⅡA sulfonate prevents the adverse left ventricular remodelling: Focus on polymorphonuclear neutrophil‑derived granule components[J]. J Cell Mol Med, 2019, 23(7):4592‑4600. DOI: 10.1111/jcmm.14306.
[6] 张珺, 何成邦, 王思雯. 丹参酮ⅡA磺酸钠注射液联合前列地尔和西地那非治疗慢性肺源性心脏病肺动脉高压临床观察[J].解放军医药杂志, 2018, 30(1):71‑73, 90. DOI: 10.3969/j.issn.2095‑140X.2018.01.019.
[7] Chen L, He W, Peng B, et al. Sodium Tanshinone ⅡA sulfonate improves post‑ischemic angiogenesis in hyperglycemia[J]. Biochem Biophys Res Commun, 2019, 520(3):580‑585. DOI: 10.1016/j.bbrc.2019.09.106.
[8] Wu TW, Zeng LH, Fung KP, et al. Effect of sodium Tanshinone ⅡA sulfonate in the rabbit myocardium and on human cardiomyocytes and vascular endothelial cells[J]. Biochem Pharmacol, 1993, 46(12):2327‑2332. DOI: 10.1016/0006‑2952(93)90624‑6.
[9] 苏梅, 秦引林, 娄雅静, 等. 丹参酮ⅡA磺酸钠体内外促血管新生作用的研究[J].现代药物与临床, 2019, 34(4):934‑940. DOI: 10.7501/j.issn.1674‑5515.2019.04.012.
[10] 陈飞, 乔祺, 王张生, 等. 丹参酮ⅡA磺酸钠在缺血性斑马鱼模型中的促血管新生作用[J].中国临床医学, 2017, 24(2):166‑170. DOI: 10.12025/j.issn.1008‑6358.2017.20160674.
[11] Zhang XD, He CX, Cheng J, et al. Sodium Tanshinone Ⅱ‑A sulfonate (DS‑201) induces vasorelaxation of rat mesenteric arteries via inhibition of l‑type Ca2+ Channel[J]. Front Pharmacol, 2018, 9:62. DOI: 10.3389/fphar.2018.00062.
[12] Yang Y, Cai F, Li PY, et al. Activation of high conductance Ca(2+)‑activated K(+) channels by sodium TanshinoneⅡ‑A sulfonate (DS‑201) in porcine coronary artery smooth muscle cells[J]. Eur J Pharmacol, 2008, 598(1‑3):9‑15. DOI: 10.1016/j.ejphar.2008.09.013.
[13] Tan X, Yang Y, Cheng J, et al. Unique action of sodium Tanshinone Ⅱ‑A sulfonate (DS‑201) on the Ca(2+) dependent BK(Ca) activation in mouse cerebral arterial smooth muscle cells[J]. Eur J Pharmacol, 2011, 656(1‑3):27‑32. DOI: 10.1016/j.ejphar.2011.01.028.
[14] Zhou Y, Liu X, Zhang X, et al. Decreased vasodilatory effect of Tanshinone ⅡA Sodium Sulfonate on mesenteric artery in hypertension[J]. Eur J Pharmacol, 2019, 854:365‑371. DOI: 10.1016/j.ejphar.2019.04.049.
[15] Yang GL, Jia LQ, Wu J, et al. Effect of Tanshinone ⅡA on oxidative stress and apoptosis in a rat model of fatty liver[J]. Exp Ther Med, 2017, 14(5):4639‑4646. DOI: 10.3892/etm.2017.5162.
[16] Zhu J, Xu Y, Ren G, et al. Tanshinone ⅡA Sodium sulfonate regulates antioxidant system, inflammation, and endothelial dysfunction in atherosclerosis by downregulation of CLIC1[J]. Eur J Pharmacol, 2017, 815:427‑436. DOI: 10.1016/j.ejphar.2017.09.047.
[17] 范全心, 苏应衡.丹参酮Ⅱ‑A磺酸钠在部分体外循环中对犬血小板的影响[J].山东医学院学报, 1985(2):78‑83. DOI:CNKI:SUN:SDYB.0.1985-02‑015.
[18] 张慧敏, 庄庆祺, 李承珠, 等. 丹参酮Ⅱ‑A磺酸钠对血小板肌动蛋白激活的Mg~(2+)‑ATP酶活性的影响[J].上海医科大学学报, 1988 (4):289‑292.
[19] Jiang KY, Ruan CG, Gu ZL, et al. Effects of Tanshinone Ⅱ‑A sulfonate on adhesion molecule expression of endothelial cells and platelets in vitro[J]. Acta Pharmacologica Sinica, 1998, 19(1):47‑50.
[20] Maione F, De Feo V, Caiazzo E, et al. Tanshinone ⅡA, a major component of Salvia milthorriza Bunge, inhibits platelet activation via Erk‑2 signaling pathway[J]. J Ethnopharmacol, 2014, 155(2):1236‑1242. DOI: 10.1016/j.jep.2014.07.010.
[21] Yang YY, Wu ZY, Zhang H, et al. LC‑MS‑based multivariate statistical analysis for the screening of potential thrombin/factor Ⅹa inhibitors from Radix Salvia Miltiorrhiza[J]. Chin Med, 2020, 15:38. DOI: 10.1186/s13020‑020‑00320‑2.
[22] Zhou ZY, Zhao WR, Zhang J, et al. Sodium Tanshinone ⅡA sulfonate: a review of pharmacological activity and pharmacokinetics[J]. Biomed Pharmacother, 2019, 118:109362. DOI: 10.1016/j.biopha.2019.109362.
[23] Yellon DM, Hausenloy DJ. Myocardial reperfusion injury[J]. N Engl J Med, 2007, 357(11):1121‑1135. DOI: 10.1056/NEJMra071667.
[24] Zhao T, Wu W, Sui L, et al. Reactive oxygen species‑based nanomaterials for the treatment of myocardial ischemia reperfusion injuries[J]. Bioact Mater, 2022, 7:47‑72. DOI: 10.1016/j.bioactmat.2021.06.006.
[25] Yang L, Zou XJ, Gao X, et al. Sodium Tanshinone ⅡA sulfonate attenuates angiotensin II‑induced collagen type I expression in cardiac fibroblasts in vitro[J]. Exp Mol Med, 2009, 41(7):508‑516. DOI: 10.3858/emm.2009.41.7.056.
[26] Zhou G, Jiang W, Zhao Y, et al. Sodium Tanshinone ⅡA sulfonate mediates electron transfer reaction in rat heart mitochondria[J]. Biochem Pharmacol, 2003, 65(1):51‑57. DOI: 10.1016/s0006‑2952(02)01447‑8.
[27] 陈恩鸿, 姚仁杰, 张月芳, 等. 丹参酮Ⅱ‑A磺酸钠对异丙基肾上腺素引起的心肌线粒体积蓄钙离子的保护作用[J].生物化学杂志, 1988(1):88‑93.
[28] 黄健平, 梁殿权, 王孝铭, 等. 丹参酮Ⅱ‑A磺酸钠(DS‑201)的心肌保护作用机制研究[J].中国病理生理杂志, 1991(2):194‑195.
[29] Cheng J, Chen T, Li P, et al. Sodium Tanshinone ⅡA sulfonate prevents lipopolysaccharide‑induced inflammation via suppressing nuclear factor‑κB signaling pathway in human umbilical vein endothelial cells[J]. Can J Physiol Pharmacol, 2018, 96(1):26‑31. DOI: 10.1139/cjpp‑ 2017‑0023.
[30] Zhang MQ, Zheng YL, Chen H, et al. Sodium Tanshinone ⅡA sulfonate protects rat myocardium against ischemia‑reperfusion injury via activation of PI3K/Akt/FOXO3A/Bim pathway[J]. Acta Pharmacol Sin, 2013, 34(11):1386‑1396. DOI: 10.1038/aps.2013.91.
[31] Yang L, Hu J, Hao HZ, et al. Sodium Tanshinone ⅡA sulfonate attenuates the transforming growth factor‑β1‑induced differentiation of atrial fibroblasts into myofibroblasts in vitro[J]. Int J Mol Med, 2015, 35(4):1026‑1032. DOI: 10.3892/ijmm.2015.2087.
[32] Chen T, Li M, Fan X, et al. Sodium Tanshinone ⅡA sulfonate prevents angiotensin ii‑induced differentiation of human atrial fibroblasts into myofibroblasts[J]. Oxid Med Cell Longev, 2018, 2018:6712585. DOI: 10.1155/2018/6712585.
[33] 杜秋明, 李忠诚, 王贵荣, 等. 丹参酮ⅡA磺酸钠对大鼠心肌缺血/再灌注心律失常的影响[J].中国中西医结合急救杂志, 2008 (3):183‑184.
[34] Shan H, Li X, Pan Z, et al. Tanshinone ⅡA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA‑1[J]. Br J Pharmacol, 2009, 158(5):1227‑1235. DOI: 10.1111/j.1476‑5381.2009.00377.x.
[35] Yang B, Lin H, Xiao J, et al. The muscle‑specific microRNA miR‑1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2[J]. Nat Med, 2007, 13(4):486‑491. DOI: 10.1038/nm1569.
[36] Takahashi K, Ouyang X, Komatsu K, et al. Sodium Tanshinone ⅡA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells[J]. Biochem Pharmacol, 2002, 64(4):745‑749. DOI: 10.1016/s0006‑2952(02)01250‑9.
[37] Yang L, Zou X, Liang Q, et al. Sodium Tanshinone ⅡA sulfonate depresses angiotensin II‑induced cardiomyocyte hypertrophy through MEK/ERK pathway[J]. Exp Mol Med, 2007, 39(1):65‑73. DOI: 10.1038/emm.2007.8.
[38] Mao S, Vincent M, Chen M, et al. Exploration of multiple signaling pathways through which sodium Tanshinone ⅡA sulfonate attenuates pathologic remodeling experimental infarction[J]. Front Pharmacol, 2019, 10:779. DOI: 10.3389/fphar.2019.00779.
[39] Wu P, Du Y, Xu Z, et al. Protective effects of sodium Tanshinone ⅡA sulfonate on cardiac function after myocardial infarction in mice[J]. Am J Transl Res, 2019, 11(1):351‑360.
[40] Chen P, An Q, Huang Y, et al. Prevention of endotoxin‑induced cardiomyopathy using sodium Tanshinone ⅡA sulfonate: involvement of augmented autophagy and NLRP3 inflammasome suppression[J]. Eur J Pharmacol, 2021, 909:174438. DOI: 10.1016/j.ejphar.2021.174438.
[41] Zhang YL, Xu JW, Wu XH, et al. Relaxant effect of sodium Tanshinone ⅡA sulphonate on mouse tracheal smooth muscle[J]. Planta Med, 2017, 83(7):624‑630. DOI: 10.1055/s‑0042‑119950.
[42] Li D, Sun D, Yuan L, et al. Sodium Tanshinone ⅡA sulfonate protects against acute exacerbation of cigarette smoke‑induced chronic obstructive pulmonary disease in mice[J]. Int Immunopharmacol, 2020, 81:106261. DOI: 10.1016/j.intimp.2020.106261.
[43] Guan R, Yao H, Li Z, et al. Sodium Tanshinone ⅡA sulfonate attenuates cigarette smoke extract‑induced mitochondrial dysfunction, oxidative stress, and apoptosis in alveolar epithelial cells by enhancing SIRT1 pathway[J]. Toxicol Sci, 2021, 183(2):352‑362. DOI: 10.1093/toxsci/kfab087.
[44] Guan R, Wang J, Li Z, et al. Sodium Tanshinone ⅡA sulfonate decreases cigarette smoke‑induced inflammation and oxidative stress via blocking the activation of MAPK/HIF‑1α signaling pathway[J]. Front Pharmacol, 2018, 9:263. DOI: 10.3389/fphar.2018.00263.
[45] Zhu Z, Li Q, Xu C, et al. Sodium Tanshinone ⅡA sulfonate attenuates silica‑induced pulmonary fibrosis in rats via activation of the Nrf2 and thioredoxin system[J]. Environ Toxicol Pharmacol, 2020, 80:103461. DOI: 10.1016/j.etap.2020.103461.
[46] Jiang L, Wang J, Ju J, et al. Salvianolic acid B and sodium Tanshinone ⅡA sulfonate prevent pulmonary fibrosis through anti‑inflammatory and anti‑fibrotic process[J]. Eur J Pharmacol, 2020, 883:173352. DOI: 10.1016/j.ejphar.2020. 173352.
[47] 陈维洲, 董月丽, 汪长根, 等. 丹参酮Ⅱ‑A磺酸钠的药理研究[J].药学学报, 1979(5):277‑283.
[48] Huang YF, Liu ML, Dong MQ, et al. Effects of sodium Tanshinone II A sulphonate on hypoxic pulmonary hypertension in rats in vivo and on Kv2.1 expression in pulmonary artery smooth muscle cells in vitro[J]. J Ethnopharmacol, 2009, 125(3):436‑443. DOI: 10.1016/j.jep.2009.07.020.
[49] Wang J, Dong MQ, Liu ML, et al. Tanshinone IIA modulates pulmonary vascular response to agonist and hypoxia primarily via inhibiting Ca2+ influx and release in normal and hypoxic pulmonary hypertension rats[J]. Eur J Pharmacol, 2010, 640(1‑3):129‑138. DOI: 10.1016/j.ejphar.2010.04.047.
[50] Wang J, Jiang Q, Wan L, et al. Sodium Tanshinone ⅡA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats[J]. Am J Respir Cell Mol Biol, 2013, 48(1):125‑134. DOI: 10.1165/rcmb.2012‑0071OC.
[51] Jiang Q, Lu W, Yang K, et al. Sodium Tanshinone ⅡA sulfonate inhibits hypoxia‑induced enhancement of SOCE in pulmonary arterial smooth muscle cells via the PKG‑PPAR‑γ signaling axis[J]. Am J Physiol Cell Physiol, 2016, 311(1):C136‑149. DOI: 10.1152/ajpcell.00252.2015.
[52] Qin W, Wang B, Lu X, et al. Determination of Sodium Tanshinone ⅡA Sulfonate in human plasma by LC‑MS/MS and its application to a clinical pharmacokinetic study[J]. J Pharm Biomed Anal, 2016, 121:204‑208. DOI: 10.1016/j.jpba.2016.01.026.
[53] Qin WW, Wang L, Jiao Z, et al. Lower clearance of sodium Tanshinone ⅡA sulfonate in coronary heart disease patients and the effect of total bilirubin: a population pharmacokinetics analysis[J]. Chin J Nat Med, 2019, 17(3):218‑226. DOI: 10.1016/S1875‑5364(19)30024‑X.
[54] Chen D, Lin XX, Huang WH, et al. Sodium Tanshinone ⅡA sulfonate and its interactions with human CYP450s[J]. Xenobiotica, 2016, 46(12):1085‑1092. DOI: 10.3109/00498254.2016.1152417.
[55] Chen Y, Tu JH, He YJ, et al. Effect of sodium Tanshinone Ⅱ A sulfonate on the activity of CYP1A2 in healthy volunteers[J]. Xenobiotica, 2009, 39(7):508‑513. DOI: 10.1080/00498250902951763.
[56] Liu J, Wang X, Cai Z, et al. Effect of Tanshinone ⅡA on the noncovalent interaction between warfarin and human serum albumin studied by electrospray ionization mass spectrometry[J]. J Am Soc Mass Spectrom, 2008, 19(10):1568‑1575. DOI: 10.1016/j.jasms.2008.06.005.
[57] Li S, Jiao Y, Wang H, et al. Sodium Tanshinone ⅡA sulfate adjunct therapy reduces high‑sensitivity C‑reactive protein level in coronary artery disease patients: a randomized controlled trial[J]. Sci Rep, 2017, 7(1):17451. DOI: 10.1038/s41598‑017‑16980‑4.
[58] 李曼, 任金妹, 谢宁. 丹参酮ⅡA磺酸钠联合西药治疗不稳定型心绞痛疗效的meta分析[J].中国现代应用药学, 2020, 37(14):1740‑1746. DOI: 10.13748/j.cnki.issn1007‑7693. 2020.14.014.
[59] 冯旭霞, 何亚. 丹参酮ⅡA磺酸钠对急性心肌梗死溶栓后缺血再灌注损伤的防护作用[J].中国生化药物杂志, 2012, 33(4):460‑462.
[60] 杜秋明, 王存选. 丹参酮ⅡA磺酸钠对心肌缺血再灌注性心律失常的保护作用[J].中华老年心脑血管病杂志, 2011, 13(4):349‑351. DOI: 10.3969/j.issn.1009‑0126. 2011.04.019.
[61] 李研. 丹参酮ⅡA对急性心肌梗死患者心功能及炎性因子的影响[J].海南医学院学报, 2016, 22(17):1933‑1935.
[62] 王承龙, 谷丰, 王少丽. 丹参酮ⅡA磺酸钠治疗冠心病心绞痛随机对照试验的Meta分析[J].中西医结合心脑血管病杂志, 2011, 9(6):644‑647.
[63] 闫薇薇, 徐国良, 秦玲. 丹参酮ⅡA磺酸钠注射液治疗冠心病心绞痛有效性及安全性的Meta分析[J].中国中医急症, 2014, 23(3):413‑415.
[64] 刘新灿. 丹参酮ⅡA磺酸钠干预对比剂肾病作用及机制研究[D]. 河南:郑州大学,2014.
[65] 康健, 赵兴山, 丁幼楠. 丹参酮ⅡA磺酸钠注射液对造影剂引起肾脏损害的作用[J]. 疑难病杂志, 2014 13(12): 1295-1296,1299. DOI:10.3969/j.issn.1671-6450.2014.12.026.
[66] Ji B, Zhou F, Han L, et al. Sodium Tanshinone IIA sulfonate enhances effectiveness Rt‑PA treatment in acute ischemic stroke patients associated with ameliorating blood‑brain barrier damage[J]. Transl Stroke Res, 2017, 8(4):334‑340. DOI: 10.1007/s12975‑017‑0526‑6.
[67] 刘施, 吴嘉瑞, 段笑娇, 等. 基于Meta分析的丹参酮Ⅱ_A磺酸钠注射液治疗急性脑梗死临床评价研究[J].药物流行病学杂志, 2017, 26(12):803‑808.
[68] Wang J, Lu W, Wang W, et al. Promising therapeutic effects of sodium Tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients[J]. J Thorac Dis, 2013, 5(2):169‑172. DOI: 10.3978/j.issn.2072‑1439. 2013.02.04.
[69] 秦宏杰, 陈新光. 丹参酮ⅡA磺酸钠注射液治疗老年肺源性心脏病的临床效果[J].中国医药导报, 2017, 14(26):130‑133.
[70] 谢晓燕, 李双双, 王永兴. 法舒地尔联合丹参酮治疗AECOPD合并肺动脉高压疗效观察[J].人民军医, 2018, 61(12):1143‑1146.
[71] 石晓萍, 李静, 潘雯, 等. 我院125例住院患者使用丹参酮ⅡA磺酸钠注射液的安全性分析[J].上海医药, 2016, 37(19):58‑63.
[72] 刘文辉. 丹参酮ⅡA磺酸钠注射液不良反应特点及使用建议[J].世界最新医学信息文摘, 2018, 18(84):115.
[73] 朱卫, 张雷. 丹参酮ⅡA磺酸钠注射液不良反应特点及使用建议[J].中国药物滥用防治杂志, 2017, 23(2):96‑98.
[74] 王华强, 王灵芝, 王秀丽. 丹参类注射液临床配伍禁忌[J].山东中医杂志, 2012, 31(4):299‑301.
[75] 曹兆流, 曹晖, 徐萍, 等. 丹参酮ⅡA磺酸钠注射液说明书以外的配伍禁忌及应对[J].中南药学, 2020, 18(4):694‑697.
[76] 曹兆流, 吴春英, 曹晖, 等. 我院2例丹参酮ⅡA磺酸钠注射液使用过程中出现絮状悬浮物的原因分析[J].中南药学, 2018, 16(11):1630‑1631.
[77] 任汝仙, 李雅琴. 丹参酮Ⅱ_A磺酸钠注射液与4种输液配伍的稳定性考察[J].中国药业, 2012, 21(13):4‑5.
[78] 冯华焯,陈豫钦,王健. 丹参来源单体药物治疗肺动脉高压的研究进展 [J/OL]. 中华心血管病杂志(网络版),2021,4:e1000091.(2021‑11‑11)[2021‑12‑08]. http://www.cvjc.org.cn/index.php/Column/columncon/article_id/267. DOI: 10.3760/cma.j.cn116031.2021. 1000091.